Screening for the fragile X: how many cells should we analyse?

Area of Science:

• Genetics
• Molecular Biology
• Screening Programs

Background:

• Nationwide screening for fragile X syndrome requires analyzing numerous individuals efficiently.
• Determining the optimal number of cells (N) for analysis is critical for cost-effective and accurate screening.
• The degree of fragile X site expression in affected individuals is a key factor in selecting N, but this data is often unknown.

Purpose of the Study:

• To estimate the impact of reducing the number of cells analyzed (N) on fragile X syndrome detection rates.
• To evaluate the potential loss in detection when N is decreased from the standard 100 cells.
• To compare the effect of reduced N on detection rates between males and females, and across different populations.

Main Methods:

• Utilized data from two large series of males and females with known fragile X site expression levels (New South Wales and Belgium).
• Simulated rescreening of these series with a reduced number of cells (N=50) to estimate missed cases.
• Assessed the fraction of affected individuals that would have been missed with a lower N.

Main Results:

• Reducing N from 100 to 50 cells in fragile X screening could decrease the detection rate by 1-5%.
• The reduction in detection rate is projected to be greater for females than for males.
• The Belgian population showed a potentially larger decrease in detection rate compared to the Australian population.

Conclusions:

• A reduction in the number of cells analyzed (N) for fragile X screening may lead to a small but significant decrease in detection rates.
• Screening protocols should carefully consider the trade-off between efficiency and detection accuracy, especially for specific demographic groups.
• Further research may be needed to optimize N based on population-specific expression levels and screening goals.